Agentix Corp. (OTCPK:AGTX) entered into an agreement and plan of merger to acquire Applied BioPharma LLC on July 13, 2021. Agentix is obligated to pay consideration of one share of common stock for the acquisition of Applied Biopharma under the terms and conditions of the merger agreement. Each Applied Biopharma LLC membership interest issued and outstanding shall be converted into the right to receive one share of common stock of Agentix. Fractional shares shall be issued if required. All the Applied Biopharma LLC membership interests shall no longer be outstanding and shall automatically be canceled and shall cease to exist, and each certificate formerly representing any of such Applied Biopharma LLC membership interests shall cease to have any rights with respect thereto, except the right to receive the merger consideration. Upon completion of the transaction, Applied Biopharma will become a wholly-owned subsidiary of the company. On July 14, 2021, the company arranged for articles of merger to be filed with Secretary of State of the State of Nevada and expects the articles of merger to be filed on or about July 15, 2021.

Agentix Corp. (OTCPK:AGTX) completed the acquisition of Applied BioPharma LLC in July, 2021.